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Abstract 
Carvedilol (Kredex, Coreg) is a multiple action antihypertensive drug that has been shown to protect cell membranes from lipid 
peroxidative damages. In this study the physical and structural effects of carvedilol on lipid bilayers are investigated by fluorescence 
techniques, differential scanning calorimetry and other physical methods. Carvedilol binds to liposomal membranes (9:1 DMPC:DMPG) 
strongly with an apparent binding constant on the order of l04 M-t in PBS (pH 7.4). The characteristic hanges in its intrinsic 
fluorescence properties when bound to liposomes uggest that this compound is situated in a non-polar environment. The Stern-Volmer 
and bimolecular quenching constants, determined using nitrate as the fluorescence quencher, for the free and bound carvedilol indicate 
that the carbazole moiety is at a depth of > 11 A in the lipid bilayer. Fluorescence anisotropy measurements show that, unlike the 
membrane probes DPH and TMA-DPH, carvedilol is relatively mobile, and does not have a rigidly-defined molecular orientation in the 
bilayers. Differential scanning calorimetry results indicate that carvedilol is an effective membrane 'fluidizer' as it dose-dependently 
lowers the gel to liquid crystalline transition temperature and broadens the endothermic transition. Comparative studies of interactions of 
carbazole, 4-OH carbazole and carvedilol with the model iposomal membranes reveal a possible role of membrane-partitioning in their 
antioxidant efficacy. These findings are discussed in perspective with the membrane biophysical properties of different classes of 
therapeutic significant lipid antioxidants in mind. 
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1. Introduction carvedilol in various in vitro models. Carvedilol inhibits 
oxygen radical-mediated lipid peroxidation in swine ven- 
Carvedilol (Kredex, Coreg) is a multiple action antihy- tricular membranes [11], human low-density lipoproteins 
pertensive drug for treatment of mild to moderate hyper- [12] and bovine and human endothelial cells [13]. We 
tension [1], and currently being evaluated in clinical trials concluded from EPR spin-trapping and structure-activity 
for utilities in chronic unstable angina and congestive heart redox potential correlation studies that carvedilol is a free 
failure. This compound has been shown to reduce infarct radical scavenger and its antioxidant activity resides mainly 
size in different models of acute myocardial infarction in its carbazole moiety [13-15]. 
[2-4]. There is significant evidence in the literature sug- The physical state of lipid bilayers has been shown to 
gesting that oxygen free radicals are involved in myocar- affect the rate of lipid peroxidation in liposomes [16]. A 
dial damage during ischemic insults [5,6] and that antioxi- number of antioxidants of therapeutic significance, such as 
dant compounds are effective in minimizing the damage the 'lazaroids' [17,18], probucol [19,20] and a-tocopherol 
[7-10]. We have investigated the antioxidant properties of [21-23], are known to selectively interact with a certain 
domain or region within the lipid bilayers and induce 
modifications in the molecular packing and dynamics of 
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in the effectiveness of these compounds as lipid peroxida- form. An appropriate volume of phosphate-buffered saline 
tion antioxidants [17-23]. To further understand the mech- (PBS) was then added into the flask and the solution was 
anism involved in the protection of cell membranes from incubated at 35°C for 20 min to allow hydration of the 
peroxidative damage by carvedilol, we investigate here the lipids at above its phase transition temperature. The solu- 
physical interaction of carvedilol with model ipid bilayers, tion was vortexed for 3 min, and the incubation/vortex 
Fluorescence techniques and differential scanning process was repeated. The resulting multilamellar vesicles 
calorimetry are used to study the effect of low concentra- (MLVs) were used for scanning calorimetry studies and 
tions of carvedilol on the temperature-dependent y amic for the preparation of small unilamellar vesicles (SUVs). 
and packing properties of synthetic liposomal membranes. The SUVs for fluorescence studies were prepared by soni- 
The characteristic ntrinsic fluorescence of carvedilol is cation of the MLV solution using a high power bath 
exploited to provide quantitative information about the sonicator (Model Gll2SP, General Laboratory Supplies 
drug-liposome binding and the location of the drug within Co., Hicksville, NY). The temperature during sonication 
the bilayer. Comparisons are made for carvedilol and two was maintained above the phase transition temperature of
structural analogs, and these findings are discussed in the the lipids. A model PCS-4700 photon correlation spec- 
context of biophysical implications relevant to their antiox- trometer (Malvern Instrument, Southborough, MA) 
idant properties, equipped with a Spectra Physics argon laser was used to 
determine the average size of the liposomes and to ensure 
the batch-to-batch reproducibility. 
2. Materials and methods 
2.3. Fluorescence spectroscopy 
2.1. Chemicals 
Fluorescence xperiments were carried out using a 
Carvedilol (I) and 4-OH carbazole (II) were obtained Model LS-100 Luminescence Spectrophotometer (Photon 
from SmithKline Beecham Pharmaceuticals. Carbazole (III) Technology International, South Brunswick, NJ) equipped 
was obtained from Aldrich. with a stroboscopic fluorescence lifetime measurement 
system with the Glan-Thompson polarizers anisotropy at- 
OH H /~ tachment. Software routines for fluorescence lifetime, po- 
/.11~N~o,~/.~y larization, anisotropy and G-factor calculations are incor- 
o o OH porated in the data acquisition software provided by the 
' ~ ~ manufacturer. All measurements were carried out in 1-cm 
thermostated cuvettes. For drug-liposomes interaction 
H H H studies, carvedilol and fluorescence probes (DPH or TMA- 
DPH) were dissolved in methanol first, then diluted into 
(I) (II) (III) the PBS or liposome solution. The final solutions contain 
1% methanol. The procedure for the determinations of the 
bimolecular quenching constants for carvedilol, carbazole 
Dimyristoylphosphatidylcholine (DMPC) and the and 4-OH carbazole was the same as that described in the 
sodium salt of dimyristoylphosphatidylglycerol (DMPG) literature for carazolol [28]. Small aliquots of concentrated 
were obtained from Avanti (Pelham, AL). Lipids were stock solution of sodium nitrate (2 M) in PBS were 
stored a t -20°C and used without further treatment. The sequentially added into the PBS or liposome solution 
fluorescence probes 1,6-diphenyl-l,3,5-hexatriene (DPH) containing 10 p.M of the test compound. The emission 
and 1-(4-trimethylammoniumphenyl)-6-phenyl-l,3,5- spectra were recorded from 335 to 380 nm with the 
hexatriene (TMA-DPH) were obtained from Molecular excitation wavelength set at 325 nm. The emission inten- 
Probes (Eugene, OR). All other chemicals were reagent sity was corrected for 'inner optical filter effect' based on 
grade, the following equation: 
2.2. Preparation of liposomes Icorr = 1 × l 0  (ae~ +Aem)/2 
where Aex and Aem are the absorbance value at the 
The procedures for preparing the synthetic phospholipid excitation (325 nm) and emission (355 nm) wavelength, 
liposomes are similar to those described in the literature respectively. The fluorescence quenching was analyzed 
[24,25]. In short, DMPC and DMPG of a pre-determined using the Stern-Volmer equation: 
ratio, with or without he drug and the fluorescence probe, Fo/F = 1 + K a [Q] 
were dissolved in chloroform. The solvent was removed 
with a rotary evaporator forming a thin film of lipids on where Fo/F is the intensity ratio in the absence and 
the wall of the round bottom flask. The flask was stored in presence of quencher concentration [Q]. The Stern-Volmer 
a vacuum desiccator overnight to remove traces of chloro- quenching constant K d was determined from the slope. 
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The bimolecular quenching constant Kq was determined carvedilol was determined as described in Section 2. The 
using the following equation, Kq = Kd/T ,  where -r is the fraction of drug bound to the liposomes can be calculated 
fluorescence lifetime of the particular carbazole compound from the known total concentration. As shown in Fig. 1, 
determined in the absence of the quencher, more than 90% of the total drug was bound to the lipo- 
somes even at the relatively low lipid concentration of 0.75 
2.4. Determination of drug-MLV binding mM. A plot of the inverse of the fraction of drug bound vs. 
the inverse of the liposome concentration was linear. An 
Drug:MLV binding constants were determined by the apparent binding constant of 9200 M-  ] was obtained from 
centrifugation method as previously described [25]. the reciprocal of the slope. 
DMPC:DMPG (9:1)MLV solutions, at a fixed total drug Having determined that carvedilol binds to the lipo- 
concentration of 10 txM and systematically varied lipid somes with a very high equilibrium affinity, we began to 
concentration i the range of 0.25 mg/ml  to 2 mg/ml,  address the issues concerning the nature of the drug-N- 
were prepared as described in the previous section. The layer interactions and the effect of the drug on the dynam- 
resulting solutions were incubated for 2 h at 37°C and ics and packing order of the bilayers. Conveniently, 
subsequently transferred into the micro-ultracentrifuge carvedilol has strong intrinsic fluorescence and its emis- 
tubes. Separation of the liposomes from the aqueous phase sion characteristics are sensitive to the change in its physi- 
was achieved using a Model TL-100 Ultracentrifuge cal environment. Carvedilol has a relatively long fluores- 
(BeckmannInstruments, Fullerton, CA) at h0 000 rpm with cence decay lifetime and its emission is effectively 
rotor model TLA 100.2 for 2 h at room temperature. The quenched by such collision quenchers as nitrate and nitrite. 
drug concentration i the supernatant was determined by These properties allow carvedilol to serve as its own 
measuring the intrinsic fluorescence of the carbazole, and membrane probe. The following fluorescence studies were 
the amount of drug bound to liposomes was determined carried out with small unilamellar vesicles (SUVs) of 9:1 
from the difference. The drug-liposome apparent binding DMPC:DMPG composition. The SUVs are optically clear 
constant K was analyzed using the double reciprocal plot. up to 100 mg/ml  and have been extensively used as a 
A plot of l/(fraction bound) vs. 1/[lipid concentration] bilayer model in drug-membrane studies using fluores- 
would yield a straight line of slope 1/K. cence techniques [26]. 
In the aqueous buffer, carvedilol displays dual emission 
2.5. Differential scanning calorimetry maxima at 345 (hi) and 355 (h2) nm with the excitation 
wavelength at 325 nm. This is shown in Fig. 2b for a 10 
DSC studies were carried out with a Microcal MC-2 txM solution of carvedilol in PBS. When SUVs are added 
Microcalorimeter (Amherst, MA). Samples were scanned into the solution, both the overall emission intensity and 
from 5 to 40°C at a rate of 20°C/h or 60°C/h. Scans were the relative intensity of X]/X 2 are increased (i.e., blue 
repeated on the same sample to check reversibility. In all shifted, Fig. 2c), indicating that carvedilol had been incor- 
cases PBS was used in the reference cell. Data were porated into a less polar environment. The liposome solu- 
analyzed using the ORGIN software provided by Microcal. tion by itself has negligible fluorescence mission in the 
The drug and liposome concentrations were as stated in the 
text and figure captions. 
1.o • 
3. Results 08 / 
In our previous study of the chemical integrity of ~= 
C-14-1abelled carvedilol in cell-based lipid peroxidation m ~ 0.6. 
assays, we have found that a large fraction of the radiola- 
bel was concentrated in the cell membranes after only a c~ = 
short period of incubation (Cheng, H.Y. and Yue, T-L., "6 0.4. 1.2 ~ 
unpublished ata). Carvedilol has an apparent partition ~ 1.1 M 
coefficient (Log D octanol/pH 7.4 buffer) of 3.22. We ~- 0.2' 1.o Y 1/[LI 
therefore anticipated that this lipophilic compound would o looo 2000 3000 
have high affinity for phospholipid vesicles. Carvedilol (10 
IxM) was incubated for 2 h at 37°C with a series of o.o 0.0 015 110 115 2:0 2'5 
liposome solutions, which contained MLVs ranging from MLV's Conc. (mg/ml) 
0.25 mg/ml  to 2 mg/ml  (0.37 mM to 2.95 mM based on 
the average molecular  weight of  679 for the 9:1 Fig. 1. Binding of carvedilol to DMPC:DMPG (9:1) multilamellar vesi- 
cles in PBS (pH 7.4). The fraction bound is determined by the centfifuga- 
DMPC:DMPG liposomes). The MLVs  were separated from tion method, as described in Section 2. The double reciprocal plot is 
the PBS by ultracentrifugation, and the amount of bound shown in the inset. 
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Fig. 3. Fluorescence anisotropy for a 10 ~M carvedilol solution in the 
200- presence of various amounts of DMPC/DMPG liposomes. 
free from liposome-bound drug. More than 95% of the 
' ~ . . . .  ~ . . . .  ~ . . . .  ~ . . . .  ~ . . . .  ~ . . . .  ~ . . . .  ~ total carvedilol is bound to liposomes at the relatively low 
340 350 360 370 380 390 400 410 
Wavelength (nm) lipid concentration of 2 mg/ml  (2.95 mM total lipid 
concentration). For the purpose of interpreting the fluores- 
Fig. 2. Fluorescence mission spectra of (a) 20 mg/ml (29.5 raM) cence and calorimetry results, we consider that the 
DMPC:DMPG SUVs in PBS, (b) 10 IxM of carvedilol in PBS, (c) 10 
IxM carvedilol+ 20 mg/ml SUVs. Excitation wavelength is at 322 nm. carvedilol is totally bound to the liposomes at > 2 mg/ml.  
The anisotropy value for carvedilol in the lipid bilayers 
is significantly lower than that for the rigidly-oriented 
wavelength range of interest (Fig. 2a). A series of solvents membrane probes DPH and TMA-DPH. As shown in Fig. 
were selected and the fluorescence mission spectra of 4, in the 5°C to 40°C temperature range the carvedilol 
carvedilol in these solvents were acquired at the excitation anisotropy remains constant while the DPH and TMA-DPH 
wavelength of 325 nm. Summarized in Table 1 are the fluorescence anisotropy follow the characteristic gel to 
emission wavelength maxima and the intensity ratio of liquid crystalline phase transition with the steepest part 
h l /k  2. The systematic blue shift of )kl//~k 2 emission is around 25°C. The experiments were carried out with each 
clearly established following the decreasing polarity order solution containing 2 mg/ml  SUVs and 5 IxM of the 
of PBS, methanol, acetonitrile and (water-saturated) oc- designated fluorescence probe (about 0.16% probe:lipid 
tanol. A comparison with the values obtained for the mole ratio). Co-incubation of 5 IxM of DPH or TMA-DPH 
liposome solution would suggest that the carvedilol and up to 50 txM of carvedilol with the SUV solution 
molecule is likely to be located in an environment with a 
solvent polarity between that of octanol and acetonitrile. 
0.35 - 
Fluorescence polarization measurements show that 
carvedilol in the presence of 20 mg/ml  SUVs has an 
o_ 0.3- 
anisotropy value of about 0.1 at room temperature. An 2 
aqueous olution of carvediiol has a negligible anisotropy ~ 025 
value. Fig. 3 shows the titration of a fixed-concentration 
(10 ~M) of carvedilol solution with liposomes in the 0 to 
25 mg/ml  range. The binding behavior is similar to that ~ 02 
observed for the MLVs using centrifugation to separate '~ o  0.15 
o • A-DPH = 
" 0.1 
Table 1 - * 
Solvent effect on carvedilol fluorescence properties 
Solvent Xl, X2(nm ) intensity(hi/X2 ) Rel. F1. Yield ~ 0.05 . . . .  , . . . .  ~ . . . .  , . . . .  , . . 0 10 20 30 40 
PBS 345,355 0.96 1 Temperature  (°C) 
Methanol 340,353 1.11 1.23 
Acetonitrile 340,354 1.12 1.21 Fig. 4. Fluorescence anisotropy measurements in the phospholipid bilayer 
Octanol 341,354 1.17 1.34 phase transition temperature ange. Carvedilol alone (5 ixM, filled dia- 
Liposomes b 344,355 1.15 2.19 mond), DPH alone (5 IxM, open circle), DPH+carvedilol (+50 ixM, 
filled circle), TMA-DPH alone (5 txM, open square), TMA-DPH+ 
" Not corrected for solvent absorption or sample scattering, carvedilol (+ 50 IxM, filled square). The DMPC/DMPG SUV concentra- 
b 20 mg/ml SUVs in PBS (pH 7.4). tion was at 2 mg/ml. 
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Fig. 5. Differential scanning calorimetry thermograms of DMPC:DMPG (9:1) MLVs. Front o back, incorporation f carvedilol with mole ratio = (1) 
drug-free, (2) 1.7%, (3) 3.4%, (4) 6.8%. The liposome concentration was 2 mg/ml, scan rate was 60°C per h; no significant differences in trends were 
observed at20°C/h. 
(1.6% drug:lipid mole ratio)does not change the tempera- the lipid bilayers. It has been demonstrated that nitrate 
ture-dependent phase transition behavior of the liposomes, quenches the fluorescence of carazolol, a carbazole-de- 
as shown in Fig. 4. The limited aqueous solubility of rived [3-adrenoceptor antagonist, and such fluorescence 
carvedilol prevented the use of higher drug concentrations property has been used for the estimation of the depth of a 
in the fluorescence membrane probe experiments, buried binding site of the receptor [28]. In aqueous olu- 
Differential scanning calorimetry proved to be a much tion, carvedilol fluorescence is also effectively quenched 
more sensitive technique for studying the effect of the drug by nitrate, as shown in Fig. 6 with the rapidly diminishing 
on the packing order of the model bilayers. Carvedilol was fluorescence intensity. By contrast, in the presence of 20 
incorporated in the lipid/chloroform mixture and sub- mg/ml  SUVs the fluorescence intensity of carvedilol is 
jected to the same evaporation/hydration/dispersion pro- minimally affected by the sequential additions of nitrate. 
cedure for the preparation of MLVs. The differential ther- Clearly, the liposome-bound drug is not accessible to the 
mogram in Fig. 5a shows a sharp peak at 24.8°C for the collisional quencher which exists only in the aqueous 
main gel to liquid crystalline transition for the drug-free phase. The Stern-Volmer quenching constant, Kd, can  be 
9:1 DMPC:DMPG liposome solution. Also observed is the determined from the slope of the plot shown in the inset. 
smaller and broader 'pre-transition' peak at 16°C. This 
calorimetric behavior is consistent with that observed in 
previous tudies using similar synthetic liposomes [27]. By 
incorporation of 1.7%, 3.3% and 6.7% mol ratio of the 1.0 ~ a--...~.__ [] [] ---o 
drug in the bilayers, the thermotropic phase transitions are 
shifted toward lower temperatures accompanied by a sys- ® =o 0 .8 - \  ~ 
tematic broadening of the peaks. The total peak areas, o 6 29~ M-' 
corresponding to the enthalpy involved, remained approxi- ~ 0.8- ~, 
mately constant (5.5 + 1.2 kcal/mol). The pre-transition ,-r ~2 - -  " ID  
peaks followed the same trend, although their positions are ._N 0.4 . . . . . . . . . .  
more difficult to determine due to the broader peak shape 
o and the much lower enthalpy. The thermotropic behavior z 0.2- 
of the carvedilol-doped liposomes is similar to that ob- 
served with other lipophilic drugs and suggests that the 
0.0 . . . . .  • . . . . . . . .  , . . . . .  
drug behaves like a membrane 'fluidizer' [25,27]. 0.0 0.1 0.2 o.3 0.4 
We have thus far established that carvedilol binds Nitrate (M) 
strongly to the lipid membrane and induces significant Fig. 6. Quenching of  carvedi lol  f luorescence by sodium nitrate in PBS 
changes in the bilayer structure. However, the data do not (filled squares) and in the presence of20 mg/ml SUVs (open squares). 
reveal information about the location of the drug within The Stern-Volmer plots are shown in the inset. 
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Fig. 7. The lowering of main transition temperature (Tin) and broadening of half-height peak width (ATI/2 shown in the inset) of MLVs with the 
incorporation f 4-OH carbazole (open circles), carbazole (filled squares) and carvedilol (open squares). The liposome concentration was 2 mg/ml (2.95 
mM). 
The K a for free carvedilol is determined to be 29.5 M - l ,  to be 8.2 and 9.0 ns, respectively. These values yield the 
practically the same as the value reported (30.7 M -1, Ref. bimolecular quenching constant 3.6 X 109 and 3.6 X 107 
[28]) for carazolol. The K d for the liposome-bound M -1 s -1 for the free and the bound carvedilol, respec- 
carvedilol is determined to be 0.32 M -1. The fluorescence tively. 
lifetime for the free and the bound carvedilol is determined In the above quenching experiments, only the location 
of the carbazole fluorophore is being probed. Therefore, 
the effect of the side chain at the 4-position on the 
Table 2 carbazole ring is not addressed by the fluorescence tech- 
Lipophilicity, fluorescence and antioxidant properties of carbazole com- nique. The differential scanning calorimetry data, on the 
pounds other hand, should reflect physical interactions of the 
Carvedilol Carbazole 4-OH Carbazole entire chemical structure of carvedilol with the lipid bilay- 
Log P 3.22 3.53 2.86 ers. Two additional compounds, 4-OH carbazole (II) and 
K(MLV) 9200 11800 2200(M -j) carbazole (III), were selected and subjected to various 
Anisotropy (SUV) 0.098 0.055 0.078 
K d (aqueous) 29.5 25.7 24.2 (M-') physico-chemical measurements in order to investigate this 
"r (aqueous) 8.2 10.3 7.3 (ns) aspect. Fig. 7 compares the thermotropic main transitions 
Kq (aqueous) 3.58 2.50 3.33 (1/M-ns) (T m) and peak width at half height (AT1/2) for different 
K d (SUV) 0.32 0.16 0.72 (M-') preparations of MLVs incorporating compound I, II or III 
"r(SUV) 9.0 13.7 8.3(ns) at several mol ratios. The ranking of carvedilol > 
Kq (SUV) N.S. N.S. N.S. 
E (vs. S.C.E.) 1.10 1.25 1.12 (volts) carbazole > 4-OH carbazole is clearly established in terms 
TBARS IC50 8.1 15 1.9 (p,M) of the drug's effect on the membrane melting character- 
istics. Other relevant physical parameters, each reflecting 
Log P = octanol/PBS pH 7.4 partition coefficient. some aspect of the drug-membrane interactions, were de- 
K = apparent liposome binding constant. 
Ko = Stern-Volmer quenching constant, termined for the three compounds and listed in Table 2. 
,r = fluorescence lifetime. They include octanol/water partition coefficient (by shake 
kq = gd/~; bimolecular quenching constant, flask method), drug-MLVs binding constant (by ultracen- 
E = oxidation potential in acetonitrile, trifugation), fluorescence anisotropy (polarization measure- 
TBARS = thiobarbituric a id reactive species (i.e., ipid peroxidation as- ment) and bimolecular quenching constant. Also included 
say). 
N.S.=no significant quenching. The calculated Kq'S are 0.036, 0.011 for comparison are our previously reported brain ho- 
and 0.087 (1/M.ns). According to Ref. [28], these values fall below the mogenate lipid peroxidation inhibition ICs0's and the oxi- 
detection limit for quenching constant error measurement, dation peak potentials [ 14]. 
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4. Discussion Kq value for liposome-bound carvedilol is below the 
detection limit of error measurement for bimolecular 
The results from the centrifugation of MLVs and the quenching constant. Tora and Strader [28] concluded that 
fluorescence anisotropy titration of SUVs clearly indicate the failure to detect any quenching of bound carazolol 
that carvedilol binds to the negatively charged phospho- indicates that the molecule is buried in the receptor protein 
lipid vesicles with a very high equilibrium affinity. With at a depth of > 11 A. The thickness of a lipid bilayer in 
the apparent binding constant at approximately 104 M- ~, a binary DMPC/DMPG mixtures has been estimated at 
rough calculation would show that, at l0 nM drug concen- 40-50 A with a 5 A interfacial 'hydrogen-bonding' region, 
tration and l0 mg/ml lipid, 90% of the total drug would on either side of the bilayers, consisting mainly of the 
be bound to the lipid phase. This is a reasonable scenario glycerol bridge. If we hypothesize that the carvedilol 
of plasma concentrations for a relatively bioavailable drug molecules are buried in the lipid bilayer at a depth of > l I 
dosed at the multi mg/kg levels. Carvedilol also binds to A, this would place the drug deep in the hydrophobic 
human low density lipoprotein with a binding constant domain. The same conclusion can be reached for carbazole 
about 1/4 of that determined in this work using the and 4-OH carbazole. 
DMPC/DMPG liposomes ([13], Cheng and Yue unpub- Incorporation of a few mol% of carvedilol into lipo- 
lished data). Taken together, the strong membrane associa- somes results in a disruption of the packing order of the 
tion of the cardioprotective drug should enhance the com- lipid bilayers. This is reflected in the lowering of the gel to 
pound's potency as a lipid peroxidation inhibitor in that liquid crystalline transition temperature and the broadening 
the drug is concentrated in cell membranes where the lipid of the endothermic transition. It should be noted that the 
peroxidation chain reactions propagate. The results from thermotropic behavior of the carvedilol-doped liposomes is 
this study also set carvedilol apart from those water-solu- comparable to that observed for the anthracycline antibi- 
ble reducing agents, such as ascorbate and thiol-containing otics [27]. Insertion of the molecule in the hydrophobic 
peptides, in terms of their antioxidant mechanisms of region of the bilayer affect bilayer dynamics uch that the 
action, motion of the acyl chains become less restrictive. One 
Carvedilol has an acid dissociation constant (pK  a) of possible role of this membrane fluidizer effect in the 
7.9 for the secondary amino function on the side chain. A antioxidant action is that it could change the mobility of 
large proportion (76%) of the compound would carry a the reactive oxygen species in the membrane and affect he 
positive charge in pH 7.4 buffer. The DMPC/DMPG rate of lipid peroxidation [16]. 
liposomes are negatively charged, thus an immediate ques- The comparative studies on carbazole, 4-OH carbazole 
tion would be whether the binding of carvedilol to lipo- and carvedilol reveal subtle differences in their interactions 
somes is simply electrostatic nteraction on the surface of with lipid bilayers. The rank order of the MLV binding 
the vesicles. Using carvediiol itself as a fluorescence mem- constants and SUV fluorescence quenching constants fol- 
brane probe, we demonstrated that the carbazole moiety is low the lipophilicity scale (as octanol/water partition co- 
not bound to the outer leaflet of the lipid bilayer. The blue efficient) of carbazole > carvedilol > 4-OH carbazole. The 
shift of its fluorescence mission and the inability of DSC results, however, show that carvedilol affects the gel 
nitrate to quench the liposome-bound drug indicates that to liquid crystalline phase transition of the liposomes to a 
the carbazole backbone is located in the hydrophobic much greater extent than either carbazole or 4-OH car- 
interior of the bilayer. Unlike the membrane probes DPH bazole. The difference may be explained if we consider 
and TMA-DPH, which are rod-shaped and thought o be that the intrinsic fluorescence r flects only the lipid envi- 
rigidly oriented with the lipid acyl chains, carvedilol does ronment around the carbazole backbone while the DSC 
not seem to occupy a particular molecular orientation in result represents the effect of the whole molecule on the 
the bilayer structure. This is evidenced by the contrast in bilayers, q~he carbazole moiety interacts trongly with the 
the fluorescence anisotropy responses over the bilayer lipophilic region of the bilayer and largely dominates the 
phase transition temperature ange (Fig. 4). Both DPH and overall binding affinity of the molecule to liposomes. The 
TMA-DPH probe the gel to liquid-crystalline fluidity greater effect of carvedilol than carbazole on the liposome 
change, while the anisotropy values for carvedilol remain phase transition temperature, despite the fact that carvedilol 
unchanged. The smaller anisotropy values also suggest that has a somewhat weaker binding constant, suggests that the 
carvedilol is more mobile than the rigidly aligned DPH long methoxyphenoxyl amino side chain indeed con- 
and TMA-DPH. tributes to the disordering of the bilayer structure. The 
We did not perform the rigorous experiments necessary relatively small fluorescence anisotropy values for the 
for a theoretical calculation of the Foster radius R 0 for the liposome-bound compounds, on the other hand, suggest 
carvedilol-nitrate fluorescence nergy transfer complex, that these molecules probably do not have a rigidly-de- 
However, since the bimolecular quenching constants (Kq'S) f ined molecular orientation i  the bilayers. 
for carvedilol are almost identical to those obtained for The amino side chain of carvedilol has a pK a value of 
carazolol, we use the published values for carazolol as an 7.9, indicating that the compound would be present mostly 
approximation for our discussion here [28]. The calculated in cationic form at physiological pH. This implies that the 
H.-Y. Cheng et al. / Biochimica et Biophysica Acta 1284 (1996) 20-28 27 
contribution of electrostatic nteraction, which we have not chain length and head group charges, could yield molecu- 
established in this study, may play a role in determining lar entities which would place the carbazole ring in a 
the binding behavior of carvedilol to liposomal mere- designated region of the bilayers with a defined structural 
branes. Investigations using cationic and neutral iposomes orientation. Further investigations may reveal optimal oca- 
at different pH's, as well as membrane structural studies tions and molecular conformations for the design of better 
incorporating carvedilol or analogs, would provide further antioxidants for the inhibition of peroxidative cell damage. 
insights into the mechanism of action of carvedilol in the 
inhibition of lipid peroxidation. 
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